LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

Kodu・Aktsiate loetelu・iRhythm Technologies Inc

iRhythm Technologies Inc

Suletud

SektorTervishoid

118.24 1.21

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

115.61

Max

119.65

Põhinäitajad
By Trading Economics
Sissetulek	-20M -14M
Müük	-9.5M 199M
Aktsiakasum	-0.35
Kasumimarginaal	-6.988
Töötajad	2,400
EBITDA	-21M -5.3M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+53.97% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	30. juuli 2026

Turustatistika
By TradingEconomics
Turukapital	-299M 3.8B
Eelmine avamishind	117.03
Eelmine sulgemishind	118.24

Uudiste sentiment

By Acuity

50%

150 / 346 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

104.78 / 137.91 Toetus ja vastupanu

iRhythm Technologies Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

12. mai 2026, 22:50 UTC

Tulu

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

12. mai 2026, 22:49 UTC

Tulu

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

12. mai 2026, 22:32 UTC

Tulu

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

12. mai 2026, 23:48 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

12. mai 2026, 22:57 UTC

Market Talk

Tulu

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

12. mai 2026, 22:26 UTC

Tulu

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

12. mai 2026, 22:25 UTC

Tulu

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

12. mai 2026, 22:25 UTC

Tulu

Aristocrat Leisure Interim Dividend A$0.50/Security

12. mai 2026, 22:24 UTC

Tulu

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

12. mai 2026, 22:23 UTC

Tulu

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

12. mai 2026, 22:23 UTC

Tulu

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

12. mai 2026, 22:19 UTC

Tulu

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

12. mai 2026, 22:14 UTC

Tulu

CBA: Business Lending Continued to Grow Above System>CBA.AU

12. mai 2026, 22:14 UTC

Tulu

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

12. mai 2026, 22:13 UTC

Tulu

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

12. mai 2026, 22:12 UTC

Tulu

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

12. mai 2026, 22:12 UTC

Tulu

CBA 3Q New Home Loan Funding A$45B>CBA.AU

12. mai 2026, 22:11 UTC

Tulu

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

12. mai 2026, 22:11 UTC

Tulu

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

12. mai 2026, 22:10 UTC

Tulu

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

12. mai 2026, 22:09 UTC

Tulu

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

12. mai 2026, 22:09 UTC

Tulu

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

12. mai 2026, 22:08 UTC

Tulu

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

12. mai 2026, 22:07 UTC

Tulu

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

12. mai 2026, 22:06 UTC

Tulu

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

12. mai 2026, 22:06 UTC

Tulu

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

12. mai 2026, 22:05 UTC

Tulu

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

12. mai 2026, 22:04 UTC

Tulu

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

12. mai 2026, 22:04 UTC

Tulu

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

12. mai 2026, 22:04 UTC

Tulu

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Võrdlus sarnastega

Hinnamuutus

iRhythm Technologies Inc Prognoos

Hinnasiht

By TipRanks

53.97% tõus

12 kuu keskmine prognoos

Keskmine 179.9 USD 53.97%

Kõrge 255 USD

Madal 147 USD

Põhineb 13 Wall Streeti analüütiku instrumendi iRhythm Technologies Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

13 ratings

Osta

Hoia

Müü

Põhineb 13 analüütiku instrumendi iRhythm Technologies Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

104.78 / 137.91Toetus ja vastupanu

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

150 / 346 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest iRhythm Technologies Inc

iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. The company also provides the Zio Monitor System, a prescription-only, remote electrocardiogram (ECG) monitoring system that consists of a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period, including specific arrhythmia events detected by the ZEUS System; the Zio XT System is the previous generation of the Zio Monitor System and is a prescription-only, remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and the Zio AT system, a prescription-only, remote ECG monitoring system that similarly consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days and the ZEUS System, but which also incorporates the Zio AT wireless gateway that provides connectivity between the Zio AT patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.